4Q0X

Crystal structure of non-neutralizing antibody in complex with Epitope II of HCV E2


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.221 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization.

Deng, L.Ma, L.Virata-Theimer, M.L.Zhong, L.Yan, H.Zhao, Z.Struble, E.Feinstone, S.Alter, H.Zhang, P.

(2014) Proc.Natl.Acad.Sci.USA 111: 10690-10695

  • DOI: 10.1073/pnas.1411317111

  • PubMed Abstract: 
  • The X-ray crystal structure of epitope II on the E2 protein of hepatitis C virus, in complex with nonneutralizing antibody mAb#12, has been solved at 2.90-Å resolution. The spatial arrangement of the essential components of epitope II (ie, the C-term ...

    The X-ray crystal structure of epitope II on the E2 protein of hepatitis C virus, in complex with nonneutralizing antibody mAb#12, has been solved at 2.90-Å resolution. The spatial arrangement of the essential components of epitope II (ie, the C-terminal α-helix and the N-terminal loop) was found to deviate significantly from that observed in those corresponding complexes with neutralizing antibodies. The distinct conformations are mediated largely by the flexibility of a highly conserved glycine residue that connects these components. Thus, it is the particular tertiary structure of epitope II, which is presented in a spatial and temporal manner, that determines the specificity of antibody recognition and, consequently, the outcome of neutralization or nonneutralization.


    Organizational Affiliation

    Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892; pei.zhang@fda.hhs.gov halter@dtm.cc.nih.gov.,Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 pei.zhang@fda.hhs.gov halter@dtm.cc.nih.gov.,Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892;,Department of Biochemistry and Molecular Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037; and.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
mAb 12 heavy chain
H
219Mus musculusMutation(s): 0 
Gene Names: Igh
Find proteins for Q99LC4 (Mus musculus)
Go to UniProtKB:  Q99LC4
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
mAb 12 light chain
L
218Mus musculusMutation(s): 0 
Gene Names: Igkc (Igk-C)
Find proteins for A2NHM3 (Mus musculus)
Go to UniProtKB:  A2NHM3
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
Envelope glycoprotein E2
E
26Hepatitis C virus genotype 1a (isolate H)Mutation(s): 0 
Find proteins for P27958 (Hepatitis C virus genotype 1a (isolate H))
Go to UniProtKB:  P27958
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.221 
  • Space Group: P 43 2 2
Unit Cell:
Length (Å)Angle (°)
a = 49.991α = 90.00
b = 49.991β = 90.00
c = 390.585γ = 90.00
Software Package:
Software NamePurpose
HKL-2000data reduction
ADSCdata collection
REFMACrefinement
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2014-04-02 
  • Released Date: 2014-07-09 
  • Deposition Author(s): Deng, L., Zhang, P.

Revision History 

  • Version 1.0: 2014-07-09
    Type: Initial release
  • Version 1.1: 2014-07-23
    Type: Database references
  • Version 1.2: 2014-08-06
    Type: Database references